# A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib

Source: https://onco.cc/trials/nct07689201/  
OnCo record `nct07689201` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Velzatinib in advanced solid tumours, run by GlaxoSmithKline, now recruiting.

## Summary

A Study of Velzatinib in Participants With Metastatic and/or Unresectable GIST After Imatinib, Sunitinib, Regorafenib, and Pimitespib is a phase 2 interventional study registered as NCT07689201 by GlaxoSmithKline, with 24 participants planned, started 2026-08-17 and due to reach its primary completion in 2027-11-29. Interventions recorded: Velzatinib.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07689201
- Phase: 2
- Setting: A Phase 2, Single-arm, Multicenter, Open-Label Study of Velzatinib (GSK6042981) in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) After Imatinib, Sunitinib, Regorafenib, and Pimitespib Therapies (StrateGIST J)
- Sponsor: GlaxoSmithKline
- Enrolled: 24

## Sources

- ClinicalTrials.gov NCT07689201: https://clinicaltrials.gov/study/NCT07689201

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [Velzatinib](https://onco.cc/drugs/velzatinib/)
- companies: [GSK](https://onco.cc/companies/gsk/)

---
JSON: https://onco.cc/api/v1/entities/nct07689201.json